It is worth mentioning that Innovent's pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference's total oral presentations. PD-1/IL-2 ...

today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada.

YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...

* Note: one patient in 0.6/1/1.5mg/kg group finished treatment without at least one post-baseline tumor assessment. Higher ORR and PFS were observed in lung adenocarcinoma patients with a history of ...

Dr. Hui Zhou, Senior Vice President of Innovent, said, "We are pleased to present an oral update on IBI343's clinical data at this year's ASCO conference. With the unique Fc-silent antibody design, ...

SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound ...

(“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today ...

SAN FRANCISCO, and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

"We are pleased to present an oral update on IBI343's clinical data at this year's ASCO conference. With the unique Fc-silent antibody design, stable linker and potent TOPO1i payload, IBI343 is ...